Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results

Taysha Gene Therapies (NASDAQ:TSHA) announced its quarterly earnings results on Wednesday. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%.

Taysha Gene Therapies Stock Down 3.2 %

Shares of TSHA traded down $0.06 on Wednesday, reaching $1.65. The company’s stock had a trading volume of 735,411 shares, compared to its average volume of 2,072,741. The firm has a fifty day moving average of $1.69 and a 200-day moving average of $1.99. Taysha Gene Therapies has a twelve month low of $1.19 and a twelve month high of $4.32. The stock has a market capitalization of $337.13 million, a PE ratio of 2.61 and a beta of 0.93. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Analyst Ratings Changes

A number of brokerages recently issued reports on TSHA. Canaccord Genuity Group lifted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. JMP Securities reissued a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Monday, January 6th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus target price of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.